Solubilization of antigen components for removal from tissues

1. A method of removing immunogenic antigens from a tissue, comprising:

a) solubilizing water-soluble antigens in the tissue by contacting the tissue with a first solution comprising a first buffering agent, a first reducing agent, a first protease inhibitor, and one or more salts suitable for maintaining protein solubility, wherein the first solution is substantially free of an amphiphile, such that the water-soluble antigens are dissolved in the first solution;

b) separating the tissue from the solubilized water-soluble antigens in the first solution;

c) solubilizing lipid-soluble antigens in the tissue by contacting the tissue with a second solution comprising a second buffering agent, a second reducing agent, a second protease inhibitor, one or more salts suitable for maintaining protein solubility and an amphiphile, such that the lipid-soluble antigens are dissolved in the second solution; and

d) separating the tissue from the solubilized lipid-soluble antigens in the second solution; thereby removing immunogenic antigens from the tissue.

2. The method of claim 1 , wherein one or more of the steps are repeated.

3. The method of claim 1 , wherein the immunogenic antigens are selected from the group consisting of protein antigens, lipid antigens and carbohydrate antigens.

4. The method of claim 1 , wherein the first buffering agent maintains a pH in the range of about 4-11.

5. The method of claim 1 , wherein the one or more salts of the first solution comprise a metal halide salt.

6. The method of claim 1 , wherein the first reducing agent is selected from the group consisting of Tributylphosphine (TBP), beta mercaptoethanol, 2-mercaptoethylamine, tris(2-carboxyethyl)phosphine (TCEP), cysteine-HCl, and dithiothreitol (DTT).

7. The method of claim 1 , wherein the water-soluble antigens are solubilized in the first solution that further comprises a chelation agent.

8. The method of claim 1 , wherein the water-soluble antigens are solubilized in the first solution comprising Tris-HCl, dithiothreitol (DTT), the first protease inhibitor, and KCl.

9. The method of claim 1 , wherein the amphiphile of the second solution is a sulfobetaine.

10. The method of claim 9 , wherein the sulfobetaine is selected from the group consisting of 3-[N,N-Dimethyl(3-myristoylaminopropyl)ammonio]propanesulfonate (amidosulfobetaine-14; ASB-14); amidosulfobetaine-16 (ASB-16); 4-n-Octylbenzoylamido-propyl-dimethylammonio sulfobetaine (ASB-C8Ø); 3-(N,N-Dimethyloctylammonio) propanesulfonate inner salt (SB3-8); N-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (SB 3-10), N-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (SB 3-12), N-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (SB 3-14); 3-(N,N-Dimethylpalmitylammonio) propanesulfonate (SB3-16); 3-(N,N-Dimethyloctadecylammonio) propanesulfonate (SB3-18); 3-(1-Pyridinio)-1-propanesulfonate (NDSB-201); 3-(Benzyldimethylammonio) propanesulfonate (NDSB-256); NDSB-211, NDSB-195, NDSB-221; 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 3-[(3-Cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPSO), and mixtures thereof.

11. The method of claim 1 , wherein the lipid-soluble antigens are solubilized in the second solution comprising Tris-HCl, dithiothreitol (DTT), the second protease inhibitor, KCl and ASB-14.

12. The method of claim 1 , wherein the method yields a substantially intact extracellular matrix (ECM) compatible with viable cell repopulation.

13. The method of claim 12 , further comprising repopulating the ECM with live cells.

14. The method of claim 1 , wherein the tissue is epithelial tissue, endothelial tissue, muscle tissue, or connective tissue.

15. The method of claim 1 , wherein the tissue is selected from the group consisting of cardiac muscle tissue, striated or skeletal muscle tissue, or smooth muscle tissue, heart, pericardium, heart valve, vessel, vascular conduit, artery, vein, skin, dermis, pericardium, dura, intestinal submucosa, ligament, tendon, bone, cartilage, ureter, urinary bladder, kidney, skin, lung, liver, and umbilical cord.

16. The method of claim 1 , wherein the tissue is an intact tissue.

17. The method of claim 1 , wherein the tissue is within or a part of an intact organ.

18. The method of claim 1 , wherein the tissue is intact tissue, the method comprising:

a) solubilizing water-soluble antigens in the tissue by contacting the tissue with the first solution comprising Tris-HCl, dithiothreitol (DTT), the first protease inhibitor, and KCl, wherein the first solution does not comprise an amphiphile, such that the water-soluble antigens are dissolved in the first solution;

b) separating the tissue from the solubilized water-soluble antigens in the first solution;

c) solubilizing lipid-soluble antigens in the tissue by contacting the tissue with a second solution comprising Tris-HCl, dithiothreitol (DTT), the second protease inhibitor, KCl and ASB 14, such that the lipid-soluble antigens are dissolved in the second solution; and

d) separating the tissue from the solubilized lipid-soluble antigens in the second solution; thereby removing immunogenic antigens from the intact tissue.

19. A method of removing immunogenic antigens from a tissue, comprising:

a) contacting the tissue with one or more cytoskeletal destabilizing agents;

b) solubilizing water-soluble antigens in the tissue;

c) separating the tissue from the solubilized water-soluble antigens;

d) solubilizing lipid-soluble antigens in the tissue; and

e) separating the tissue from the solubilized lipid-soluble antigens; thereby removing immunogenic antigens from the tissue.

20. The method of claim 19 , wherein the one or more cytoskeletal destabilizing agents comprise one or more actin depolymerization agents.

21. The method of claim 19 , wherein the one or more cytoskeletal destabilizing agents comprise one or more microtubule depolymerization or destabilizing agents.

22. A method of removing immunogenic antigens from a muscle tissue, comprising:

a) relaxing the muscle tissue in a relaxing solution comprising an energy source molecule;

b) contacting the muscle tissue with one or more cytoskeletal destabilizing agents;

c) contacting the muscle tissue with a concentrated salt solution;

d) solubilizing water-soluble antigens in the tissue;

e) separating the muscle tissue from the solubilized water-soluble antigens;

f) solubilizing lipid-soluble antigens in the tissue; and

g) separating the muscle tissue from the solubilized lipid-soluble antigens; thereby removing immunogenic antigens from the muscle tissue.

23. The method of claim 22 , wherein one or more of the steps are repeated.

24. The method of claim 22 , wherein the steps are performed in an order selected from the group consisting of:

i) a), b), c), d), e), f) and g);

ii) a), f), g), b), c), d) and e);

iii) a), d), e), b), c), f) and g);

iv) a), d), e), f), g), b) and c);

v) a), b), c), d), e), f), g), b), c), and e); and

vi) a), f), g), b), c), d), e), f), and g).

25. The method of claim 22 , wherein the muscle tissue is cardiac muscle tissue, striated or skeletal muscle tissue, or smooth muscle tissue.

26. The method of claim 22 , wherein the method comprises the step of relaxing the muscle tissue prior to contacting the tissue with one or more cytoskeletal destabilizing agents.

27. The method of claim 22 , wherein the muscle tissue is relaxed in a relaxing solution comprising an energy source molecule.

28. The method of claim 27 , wherein the energy source molecule is selected from the group consisting of a nucleotide 5′-triphosphate (NTP), adenosine, inosine, aspartate, glutamate, creatine phosphate, a Kreb's cycle precursor or intermediate, glucose, and dextrose.

29. The method of claim 27 , wherein the energy source molecule is a Pyrophosphate (PPi) or a nucleotide 5′-triphosphate (NTP) selected from the group consisting of adenosine 5′-triphosphate (ATP), inosine 5′-triphosphate (ITP), guanidine 5′-triphosphate (GTP), cytidine 5′-triphosphate (CTP), and uridine 5′-triphosphate (UTP).

30. The method of claim 27 , wherein the energy source molecule is a precursor of adenosine 5′-triphosphate (ATP).

31. The method of claim 22 , wherein the relaxing solution further comprises a calcium ion chelating agent.

32. The method of claim 22 , wherein the relaxing solution further comprises a permeabilization agent.

33. The method of claim 22 , wherein concentrated salt solution comprises one or more salts in a concentration range from about 0.5 M to about 3.0 M.

34. The method of claim 22 , wherein the concentrated salt solution comprises one or more metal halide salts.

35. The method of claim 22 , wherein sarcomeric constituents are not detectable in the muscle tissue.